<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006263</url>
  </required_header>
  <id_info>
    <org_study_id>2016YF021-02</org_study_id>
    <nct_id>NCT03006263</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer</brief_title>
  <official_title>Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore clinical outcomes of totally laparoscopic versus
      laparoscopy assisted total gastrectomy for gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall postoperative morbidity rates</measure>
    <time_frame>30 days</time_frame>
    <description>Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative morbidity rates</measure>
    <time_frame>1 day</time_frame>
    <description>The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation in hours is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first flatus in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first liquid diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first soft diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first soft diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>30 days</time_frame>
    <description>Visual analog pain score method is used to evaluate the difference of postoperative pain degree.The score of postoperative pain is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of weight</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The variation of weight on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of cholesterol</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The variation of cholesterol in millimole/liter on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of endoscopy</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>The incidence of reflux esophagitis under the endoscopy on postoperative 3 and 12 months are used to access the postoperative quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of body temperature</measure>
    <time_frame>8 days</time_frame>
    <description>The daily highest body temperature in degree centigrade before discharge are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of white blood cell count</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of hemoglobin</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of C-reactive protein</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of C-reactive protein IN milligram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Totally Laparoscopic Total Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopy Assisted Total Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Totally Laparoscopic Total Gastrectomy</intervention_name>
    <description>After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.</description>
    <arm_group_label>Totally Laparoscopic Total Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopy Assisted Total Gastrectomy</intervention_name>
    <description>After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.</description>
    <arm_group_label>Laparoscopy Assisted Total Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 to 75 years old

          2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or
             poorly differentiated) confirmed pathologically by endoscopic biopsy

          3. Locally advanced tumor in the middle third stomach（cT1-4a, N-/+, M0 at preoperative
             evaluation according to the AJCC(American Joint Committee on Cancer) Cancer Staging
             Manual Seventh Edition）

          4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby
             in the preoperative examinations

          5. Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale

          6. ASA (American Society of Anesthesiology) class I to III

          7. Written informed consent

        Exclusion Criteria:

          1. Pregnant and lactating women

          2. Suffering from severe mental disorder

          3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)

          4. History of previous gastric surgery (including ESD/EMR (Endoscopic Submucosal
             Dissection/Endoscopic Mucosal Resection )for gastric cancer)

          5. Enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative
             imaging including enlarged or bulky No.10 lymph node

          6. History of other malignant disease within the past 5 years

          7. History of previous neoadjuvant chemotherapy or radiotherapy

          8. History of unstable angina or myocardial infarction within the past 6 months

          9. History of cerebrovascular accident within the past 6 months

         10. History of continuous systematic administration of corticosteroids within 1 month

         11. Requirement of simultaneous surgery for other disease

         12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by
             gastric cancer

         13. FEV1＜50% of the predicted values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changming Huang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital,China</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2016</study_first_submitted>
  <study_first_submitted_qc>December 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>December 26, 2016</last_update_submitted>
  <last_update_submitted_qc>December 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Totally Laparoscopic Total Gastrectomy</keyword>
  <keyword>Laparoscopy Assisted Total Gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

